Today: 11 April 2026
Subscribe
Browse Category

NYSE:MRK 27 December 2025 - 9 January 2026

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck shares rose 1.5% to $110.20 after Wolfe Research upgraded the stock and set a $135 price target. Merck completed its $221.50-per-share tender offer for Cidara and flagged a $9 billion R&D charge for 2026. Investors watched fallout from a U.S. shift to a single-dose HPV vaccine recommendation ahead of Merck’s Feb. 3 results.
8 January 2026
····
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck shares rose 1.1% to $108.60 Tuesday, hitting a 52-week high of $110.16 amid investor focus on U.S. vaccine schedule changes and upcoming CEO remarks at the J.P. Morgan Healthcare Conference Jan. 12. The company’s Gardasil HPV vaccine faces uncertainty after the CDC shifted to a single-dose recommendation, while an FDA decision on Keytruda in ovarian cancer is expected Feb. 20.
6 January 2026
··
Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck stock starts 2026 higher as Cidara tender-offer deadline hits next week

Merck shares rose 1.2% to $106.45 Friday after Nasdaq set Jan. 6 as the expiration for its $9.2 billion cash tender offer for Cidara Therapeutics. Cidara shares will be halted after Jan. 6 and suspended Jan. 8 if the merger closes as planned. Merck’s move snapped a three-day losing streak, leaving the stock just below its 52-week high. About 10 million shares traded, below the 50-day average.
3 January 2026
···
Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson stock ticks up after $1.30 dividend; earnings next on the radar

Johnson & Johnson closed Friday up 0.19% at $207.35 after declaring a $1.30-per-share quarterly dividend, payable March 10 to shareholders of record as of Feb. 24. The stock traded between $203.68 and $207.37 during the session. Investors await J&J’s Jan. 21 earnings call and next week’s U.S. labor data. The S&P 500 finished up 0.19%.
3 January 2026
·····
Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck (MRK) stock holds steady as Wall Street cools into year-end trade

Merck shares edged up a penny to $106.79 in Monday afternoon trading, moving in a tight range on volume of about 4.1 million. The Health Care Select Sector SPDR ETF slipped 0.05% as health-care stocks held steady while major indexes fell. Investors are awaiting Fed minutes and monitoring year-end market signals. Merck’s next earnings report is set for February 3.
29 December 2025
Merck stock holds steady as year-end trading thins and Wall Street slips

Merck stock holds steady as year-end trading thins and Wall Street slips

Merck shares slipped 0.1% to $106.68 midday Monday, outperforming broader U.S. markets as the S&P 500 ETF fell 0.6% and the Nasdaq-100 tracker dropped 0.7%. Trading volumes remained thin ahead of Federal Reserve minutes due Tuesday. Investors await Merck’s Feb. 3 earnings call for 2026 guidance and pipeline updates. Pending U.S. home sales rose 3.3% in November, beating forecasts.
29 December 2025
··
1 2 3 4 5 6 7

Stock Market Today

  • Varonis Systems Shares Drop 6.7% Amid Sector-Wide AI Concerns
    April 10, 2026, 11:13 PM EDT. Shares of data security firm Varonis Systems (NASDAQ: VRNS) tumbled 6.7% following a UBS downgrade of ServiceNow, which triggered a broader sell-off in enterprise software stocks. Investors fear "seat compression," where AI-driven automation reduces the number of users needed, threatening per-seat revenue models used by companies like Salesforce and Adobe. Recent advancements by AI-native rivals and startups have intensified these concerns. Varonis's stock, already down 37.2% year-to-date and over 68% below its 52-week high, is notably volatile with 16 major moves exceeding 5% in the past year. The ongoing shift toward AI-managed software tools challenges traditional subscription-based software-as-a-service (SaaS) firms and casts uncertainty on legacy business models.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:39 PM EDT Varonis Systems Shares Drop 6.7% Amid Sector-Wide AI Concerns April 10, 2026, 11:13 PM EDT. Shares of data security firm Varonis Systems (NASDAQ: VRNS) tumbled 6.7% following a UBS downgrade of ServiceNow, which triggered a broader sell-off in enterprise software stocks. Investors fear "seat compression," where AI-driven automation reduces the number of users needed, threatening per-seat revenue models used by companies like Salesforce and Adobe. Recent advancements by AI-native rivals and startups have intensified these concerns. Varonis's stock, already down 37.2% year-to-date and over 68%
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop